Atara Biotherapeutics, Inc. (ATRA) — Financial statements
Income statement, balance sheet, and cash flow for Atara Biotherapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 121↓6.3% | 129↑1404.0% | 9↓86.5% | 64↑212.6% | 20 | |
| Cost of Revenue | 21↑1.0% | 21↑136.4% | 9 | 0.00↓100.0% | 282 | |
| Gross Profit | 100↓7.8% | 108↑34582.7% | -0.31↓100.5% | 64↑124.3% | -262 | |
| Operating Expenses | ||||||
| R&D Expenses | 37↓75.3% | 151↓32.6% | 225↓17.5% | 273↓3.4% | 282 | |
| General & Administrative Expenses | 26↓34.2% | 40↓21.7% | 51↓28.9% | 72↓9.2% | 79 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 26↓34.2% | 40↓21.7% | 51↓28.9% | 72↓9.2% | 79 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -282 | |
| Operating Expenses | 64↓66.7% | 191↓30.6% | 276↓19.9% | 344↑336.7% | 79 | |
| Total Costs & Expenses | 85↓60.0% | 212↓25.4% | 285↓17.3% | 344↓4.6% | 361 | |
| Operating Results | ||||||
| Operating Income | 36↑143.0% | -83↑69.8% | -276↑1.6% | -281↑17.6% | -340 | |
| Depreciation & Amortization | 2↓58.1% | 5↑4.6% | 5↓14.6% | 6↓39.5% | 9 | |
| EBITDA | 39↑151.0% | -76↑71.5% | -266↓19.7% | -222↑32.9% | -331 | |
| EBIT | 37↑145.2% | -81↑70.2% | -271↓18.8% | -228↑33.1% | -340 | |
| Interest & Other Income | ||||||
| Net Interest Income | -3↓24.1% | -3↓1876.6% | 0.14↓94.8% | 3↑631.9% | 0.37 | |
| Interest Income | 0.68↓67.6% | 2↓61.1% | 5↑77.4% | 3↑733.5% | 0.37 | |
| Interest Expense | 4↓17.8% | 5↓12.7% | 5↑1316.9% | 0.37 | 0.00 | |
| Non-Operating Income | -0.65↑75.4% | -3↑49.1% | -5↑90.2% | -53 | 0.00 | |
| Other Income / Expenses | -3↓59.0% | -2↓1782.9% | -0.11↓100.2% | 52↑14129.7% | 0.37 | |
| Income Before Tax | 33↑138.3% | -85↑69.1% | -276↓20.9% | -228↑32.9% | -340 | |
| Income Tax Expense | 0.03↑358.3% | -0.01↓180.0% | 0.02↑25.0% | 0.01↓73.9% | 0.05 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 33↑138.3% | -85↑69.1% | -276↓20.9% | -228↑32.9% | -340 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 33↑138.3% | -85↑69.1% | -276↓20.9% | -228↑32.9% | -340 | |
| Bottom-Line Net Income | 33↑138.3% | -85↑69.1% | -276↓20.9% | -228↑32.9% | -340 | |
| EPS (Basic) | 2.61↑122.9% | -11.41↑82.5% | -65.18↓16.5% | -55.96↑38.4% | -90.78 | |
| EPS (Diluted) | 2.57↑122.5% | -11.41↑82.5% | -65.18↓16.5% | -55.96↑38.4% | -90.78 | |
| Weighted Average Shares | 13↑67.5% | 7↑76.8% | 4↑3.8% | 4↑8.9% | 4 | |
| Weighted Average Diluted Shares | 13↑69.8% | 7↑76.8% | 4↑3.8% | 4↑8.9% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.